The offering refinances near-term maturities (EUR 500M Dec 2026 and $600M Feb 2027 notes) and extends debt maturity profile. Monitor use of proceeds for debt repayment versus share repurchases or M&A. The concurrent USD notes offering adds $500M of additional debt capacity if completed.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $107.32entry
- T+1 · 6d ago +0.14%α −1.18% · $107.47
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zimmer Biomet is issuing EUR 500 million of 4.375% notes due 2033, with net proceeds of approximately EUR 496.4 million (about $556.9 million) to be used for general corporate purposes including potential repayment of near-term maturing debt (EUR 500M 2.425% notes due Dec 2026 and/or $600M 4.700% notes due Feb 2027). The offering is a debt refinancing and capital management move, announced alongside a concurrent $500M USD notes offering. The company reported Q3 2026 results five days prior with modest revenue growth and raised full-year guidance.
Key Financial Metrics
Key Facts
- EUR 500,000,000 aggregate principal amount of 4.375% notes due November 12, 2033
- Net proceeds to issuer approximately EUR 496.4 million (about $556.9 million at EUR/USD 1.1219)
- Use of proceeds includes general corporate purposes, potential repayment of EUR 500M 2.425% notes due Dec 2026 and/or $600M 4.700% notes due Feb 2027, share repurchases, and acquisitions
- Concurrent offering of $500M 5.850% notes due 2036 announced; neither offering conditioned on the other
- Notes are unsecured, unsubordinated obligations; rank equally with existing unsecured debt
- Underwriters include Barclays, Citigroup, HSBC, Morgan Stanley, RBC Capital Markets, and others
- Underwriting discount of 0.400%; proceeds before expenses 99.594% of principal
- Q3 2026 results (filed Nov 4): net sales $2.063B (+3.1% reported), adjusted EPS $1.90, GAAP EPS $1.00; full-year guidance raised
- At September 30, 2026, approximately $7.5 billion of consolidated indebtedness outstanding, none subsidiary debt
Financial Impact
EUR 500 million debt issuance; net proceeds ~EUR 496.4 million; concurrent $500M USD notes offering
Risk Factors
- Increased total debt and interest expense
- Euro-denominated notes expose holders to FX risk
- No established trading market for the notes; listing on NYSE not guaranteed
- Potential conflict of interest as underwriters may hold existing notes being refinanced
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-453563 |
| Document: d180022dexfilingfees.htm | 0001193125-26-453563 |
| Document: 0001193125-26-453563-index-headers.html | 0001193125-26-453563 |
| Document: 0001193125-26-453563-index.html | 0001193125-26-453563 |
| Document: 0001193125-26-453563.txt | 0001193125-26-453563 |
Track record
17 reports on ZBH
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +8.74% at T+60 after the Apr 28, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $103.21 Now $101.41 −1.74% settles Nov 20
- Nov 9, 20267d ago 424B5 Neutral 3/10 Entry $107.32 Now $101.41 −5.51% settles Nov 17
- Nov 9, 20267d ago 424B5 Neutral 3/10 Viewing Entry $107.32 Now $101.41 −5.51% settles Nov 17
- Nov 5, 202611d ago 424B5 Neutral 3/10 Entry $106.85 to $104.56 Now $101.41 −5.09% ▼ −2.14% −5.43% vs SPY
- Nov 5, 202611d ago 424B5 Neutral 2/10 Entry $106.85 to $104.56 Now $101.41 −5.09% ▼ −2.14% −5.43% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $110.15 to $107.47 Now $101.41 −7.93% ▼ −2.43% −1.52% vs SPY
- Oct 26, 202621d ago Institutional Cluster Bearish 4/10 Entry $97.44 to $94.52 Now $101.41 −4.07% ▲ +3.00% +1.74% vs SPY
- Oct 21, 202627d ago Court Ruling Bearish 6/10 Entry $98.81 to $97.47 Now $101.41 −2.63% ▲ +1.36% +2.06% vs SPY
- Sep 15, 20268w ago Insider Cluster Neutral 3/10 Entry $96.53 to $90.64 Now $101.41 +5.06% ▼ −6.10% −8.17% vs SPY
- Sep 2, 202610w ago Court Ruling Neutral 2/10 Entry $98.66 to $93.24 Now $101.41 +2.79% ▼ −5.49% −4.34% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers